menu
    • menu
    [{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Hydromethylthionine","moa":"Microtubule-associated protein tau (MAPT)","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TauRx Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Hydromethylthionine","moa":"Microtubule-associated protein tau (MAPT)","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TauRx Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Hydromethylthionine","moa":"Microtubule-associated protein tau (MAPT)","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TauRx Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Hydromethylthionine","moa":"Microtubule-associated protein tau (MAPT)","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TauRx Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Hydromethylthionine","moa":"Microtubule-associated protein tau (MAPT)","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TauRx Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Hydromethylthionine","moa":"Microtubule-associated protein tau (MAPT)","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TauRx Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Hydromethylthionine

    Menu

    Hydromethylthionine

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            TauRx Therapeutics

                            Singapore arrow
                            CPhI India
                            Not Confirmed

                            TauRx Therapeutics

                            Singapore arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydromethylthionine

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TRx0237 for the Treatment of Early and Mild-Moderate Alzheimer's Disease

                            Details : TRx0237 is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 29, 2018

                            Lead Product(s) : Hydromethylthionine

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            TauRx Therapeutics

                            Singapore arrow
                            CPhI India
                            Not Confirmed

                            TauRx Therapeutics

                            Singapore arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydromethylthionine

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment

                            Details : TRx0237 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 26, 2018

                            Lead Product(s) : Hydromethylthionine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            TauRx Therapeutics

                            Singapore arrow
                            CPhI India
                            Not Confirmed

                            TauRx Therapeutics

                            Singapore arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydromethylthionine

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

                            Details : TRx0237 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 21, 2012

                            Lead Product(s) : Hydromethylthionine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            TauRx Therapeutics

                            Singapore arrow
                            CPhI India
                            Not Confirmed

                            TauRx Therapeutics

                            Singapore arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydromethylthionine

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease

                            Details : TRx0237 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 21, 2012

                            Lead Product(s) : Hydromethylthionine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            TauRx Therapeutics

                            Singapore arrow
                            CPhI India
                            Not Confirmed

                            TauRx Therapeutics

                            Singapore arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydromethylthionine

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFT...

                            Details : TRx0237 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Frontotemporal Dementia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 22, 2012

                            Lead Product(s) : Hydromethylthionine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            TauRx Therapeutics

                            Singapore arrow
                            CPhI India
                            Not Confirmed

                            TauRx Therapeutics

                            Singapore arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydromethylthionine

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease

                            Details : TRx0237 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 22, 2012

                            Lead Product(s) : Hydromethylthionine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth